13G Filing: Biotechnology Value Fund LP and Spero Therapeutics Inc (SPRO)

Page 10 of 13

Page 10 of 13 – SEC Filing

Item 2(d). Title of Class of Securities:

Common Stock, $0.001 par value (the “Common Stock”)

Item 2(e). CUSIP Number:

84833T103

Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person
Filing is a:
/x/ Not applicable.
(a) / / Broker or dealer registered under Section 15 of the Exchange Act.
(b) / / Bank as defined in Section 3(a)(6) of the Exchange Act.
(c) / / Insurance company as defined in Section 3(a)(19) of the Exchange Act.
(d) / / Investment company registered under Section 8 of the Investment Company Act.
(e) / / An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E).
(f) / / An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F).
(g) / / A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G).
(h) / / A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
(i) / / A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act.
(j) / / Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
(k) / / Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____
Item 4. Ownership
(a) Amount beneficially owned:

As of the close of business on November
9, 2017 (i) BVF beneficially owned 510,846 shares of Common Stock, (ii) BVF2 beneficially owned 326,647 shares of Common Stock,
and (iii) Trading Fund OS beneficially owned 87,695 shares of Common Stock.

Partners OS, as the general partner
of Trading Fund OS, may be deemed to beneficially own the 87,695 shares of Common Stock beneficially owned by Trading Fund OS.

10

Follow Spero Therapeutics Inc. (NASDAQ:SPRO)

Page 10 of 13